PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
Rhea-AI Summary
PDS Biotech (Nasdaq: PDSB) will host a conference call and webcast on March 30, 2026 at 8:00 a.m. ET to report fourth‑quarter and year‑end financial results for the period ended December 31, 2025, and to provide a clinical programs and corporate update.
Access details: domestic dial‑in 1‑877‑704‑4453, international 1‑201‑389‑0920, conference ID 13759288. A webcast will be archived on the company website for six months.
Positive
- None.
Negative
- None.
News Market Reaction – PDSB
In the Mar 25 session, PDSB gained 15.38%, reflecting a significant positive market reaction. Argus tracked a peak move of +19.5% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings call schedule | Neutral | -1.8% | Scheduled Q3 2025 results call and webcast with clinical program update. |
| Aug 06 | Earnings call schedule | Neutral | -1.8% | Announced Q2 2025 results conference call and webcast at 8:00 AM ET. |
| May 07 | Earnings call schedule | Neutral | -2.5% | Set Q1 2025 financial results call with accompanying clinical updates. |
| Mar 18 | Earnings call schedule | Neutral | +3.7% | Planned full year 2024 results call and pipeline review at 8:00 AM ET. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior conferences/earnings call scheduling headlines for PDSB have led to modest, often slightly negative moves, with an average reaction of about -0.59% around such notices.
Over the past year, PDS Biotech has routinely announced conference calls to discuss quarterly and annual results alongside clinical updates. Four prior conferences,earnings notices from Mar 18, 2025 through Nov 6, 2025 all followed a similar format: scheduling an 8:00 a.m. ET call, reviewing financial performance, and highlighting pipeline progress. Price reactions around these events clustered near an average of -0.59%, suggesting that scheduling updates alone have historically had limited directional impact.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30, 2026 at 8:00 am Eastern Time.
| Conference Call Details |
| Date: March 30, 2026 |
| Time: 8:00 a.m. Eastern Time |
| Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International) |
| Conference I.D.: 13759288 |
| Webcast: Click Here |
| CallMe™: Click Here (available 15 minutes prior to the call) |
After the live webcast, the event will be archived on PDS Biotech’s website for six months.
About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy PDS0101 is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. PDS01ADC is being evaluated in multiple phase 2 trials in various cancer indications in combination with standard of care.
For more information, please visit www.pdsbiotech.com
Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0101 (Versamune® HPV), PDS01ADC, PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 (Versamune® HPV), PDS01ADC, PDS0103 (Versamune® MUC1) and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Versamune® is a registered trademark of PDS Biotechnology Corporation.
Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com
Media Contact:
Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com
